Lexington, Mass., October 22, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, today announced the appointment of John Lepore, M.D., to the company’s board of directors. Dr. Lepore brings over 20 years of leadership experience in R&D and drug discovery to KSQ’s…

Lexington, Mass., October 8, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, today announced the appointment of Anna Truppel-Hartmann, M.D., as Chief Medical Officer. Dr. Truppel-Hartmann brings an accomplished track record in clinical development, medical affairs, patient engagement, and talent development. She…

Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumors Lexington, Mass., September 24, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson)…

Lexington, Mass., August 28, 2024 – KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, today announced that management will participate in the following investor conferences in September 2024: Morgan Stanley 22nd Annual Global Healthcare Conference (New York, NY) on Wednesday, September…

Lexington, Mass., June 12, 2024 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1/2 clinical study of KSQ-001EX, a novel edited TIL therapy. KSQ-001EX consists of TIL in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene…

Phase 1/2 clinical study will evaluate the safety, pharmacokinetics, and preliminary efficacy of KSQ-001EX in melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer  Lexington, Mass., November 29, 2023 — KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, in collaboration with The University…

Collaboration will provide full process development and manufacturing support for KSQ’s lead eTIL programs Lexington, Mass., September 6, 2023 — KSQ Therapeutics, Inc. (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, and CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center, announced today…

Lexington, Mass., July 13, 2023 — KSQ Therapeutics, Inc. (“KSQ”), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, announced today it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279. KSQ-4279 is a first-in-class, potent, and selective small…

Expanded collaboration focused on novel target discovery and validation to inform the development of targeted therapies that address resistance mechanisms in patients with cancer Agreement expands the companies’ successful ongoing collaboration focused on discovering natural killer (NK) and T-cell targets Lexington, Mass., May 17, 2023 KSQ Therapeutics, (“KSQ”), a clinical-stage biotechnology…

Lexington, Mass., January 25, 2023 KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics platform, announced today that Ono Pharmaceutical Co., Ltd. (“ONO”), has acquired multiple research-stage DNA damage response (DDR) programs identified using KSQ’s CRISPRomics platform technology. All…

Lexington, Mass., December 8, 2022 – KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics® platform, today announced the appointment of Mahesh Karande, President and CEO of Omega Therapeutics, to the company’s board of directors. “Mahesh’s deep experience in…

Lexington, Mass., December 7, 2022- KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics® platform, today announced the initiation of dosing in the combination therapy portion of Study KSQ-4279-1101, a Phase 1 clinical study of KSQ-4279 in patients with…

Micah Benson, PhD, promoted to Chief Scientific Officer  Tom Leitch joins as Chief Technology Officer  Outgoing CSO Frank Stegmeier, PhD, transitions to board of directors Lexington, Mass., September 23, 2022- KSQ Therapeutics, a clinical-stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics®…

– Data supports ongoing Phase 1 study of KSQ-4279, a first-in-class USP1 inhibitor, in patients with advanced solid tumors CAMBRIDGE, Mass., March 22, 2022- KSQ Therapeutics (KSQ), a clinical stage biotechnology company developing therapies to treat cancer and autoimmune diseases using its proprietary, integrated discovery CRISPRomics® platform, will give an…

Click to download PDF file.

Click image to enlarge. Click to download PDF file.

CAMBRIDGE, Mass., September 22, 2021 – KSQ Therapeutics, a biotechnology company developing drugs to treat cancer and autoimmune diseases using its proprietary, integrated discovery platform to systematically screen the whole genome in cancer and immune cells, today announced that Qasim Rizvi, Chief Executive Officer of KSQ, will present at the…

CAMBRIDGE, Mass., September 14, 2021- KSQ Therapeutics, a biotechnology company developing drugs to treat cancer and autoimmune diseases using its proprietary, integrated discovery platform to systematically screen the whole genome in cancer and immune cells, today announced the initiation of dosing in a Phase 1 clinical study of KSQ-4279, a…

CAMBRIDGE, Mass., May 13, 2021– KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the appointment of Chris Heberlig, MBA, as Chief Financial Officer. “Chris is an seasoned biotech finance…

CAMBRIDGE, Mass., March 10, 2021- KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced that the company is scheduled to present at the Oppenheimer 31st Annual Healthcare Conference, to be…

CAMBRIDGE, Mass., February 1, 2021- KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced key strategic management changes, promoting Micah Benson, Ph.D., to Senior Vice President and Head of Immunobiology…

Dr. Rizvi brings a Proven Track Record and Commitment to Innovation, Collaboration & Team Building CAMBRIDGE, Mass., January 25, 2021 – KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced…

Collaboration includes two T-cell programs and an expansive discovery program to identify natural killer (NK) cell targets Potential for more than $100M in upfront and preclinical milestone payments, and eligible to receive additional development and commercialization milestone payments for each product KSQ retains a U.S. cost/profit-sharing option on one product,…

2020 ENA Plenary Slide Deck: “USP1 inhibitors show robust combination activity and a distinct resistance profile from PARP inhibitors” 2020 ENA Poster: “Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers” Data demonstrate robust single agent, combination activity and distinct resistance profile from PARP inhibitors…

CAMBRIDGE, Mass., Sept. 24, 2020– KSQ® Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, announced it will present new data from its USP1 inhibitor program at the 32nd EORTC-NCI-AACR Symposium on Molecular…

Click to download PDF file.

Click to download PDF file.

Data demonstrate potential to increase efficacy of TIL adoptive cell therapy in preclinical models CAMBRIDGE, Mass., February 9, 2020 – KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the…

Gaithersburg, MD and Cambridge, MA – December 4, 2019: MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new development…

Lead program declared as small molecule inhibitor of novel target in DDR pathway for the treatment of ovarian and breast cancers CAMBRIDGE, Mass., December 3, 2019 – KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that…

Click to download PDF file.

– Posters at AACR-NCI-EORTC and SITC illustrate genome-wide, in vivo T-cell approach to identify and validate novel therapeutic immuno-oncology targets – CAMBRIDGE, Mass., October 28, 2019 – KSQ Therapeutics, a biotechnology company using CRISPR technology to enable the company’s powerful discovery engine to achieve higher probabilities of success in drug…

– CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs – – KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous cell therapies, including its existing eTILTM cell franchise – ZUG, Switzerland and CAMBRIDGE, Mass., October 15, 2019 – CRISPR…

– Company’s Pipeline Spans Three Oncology Drug Categories: Adoptive T‑Cell Therapies, Immuno-Oncology Monotherapies and Targeted Therapies – – Proprietary CRISPRomics™ Discovery Engine Has Yielded 12 Oncology Drug Discovery Programs in 12 Months – CAMBRIDGE, Mass. – September 28, 2018 – KSQ Therapeutics announced today that the company has secured an…

– Industry Leader Brings Expertise in Medical, Clinical and Regulatory Affairs in Drug Development – Cambridge, Mass., September 25, 2018 – KSQ Therapeutics today announced the appointment of Richard A. Moscicki, MD, to the company’s Board of Directors. Dr. Moscicki brings more than 25 years of leadership experience in translational…

– World class executive team led by CEO David Meeker and CSO Frank Stegmeier – – Proprietary CRISPRomics™ Drug Discovery Engine Pinpoints the Best Therapeutic Nodes of Diseases; Product Insights Being Translated into Drug Candidates – Cambridge, Mass., October 2, 2017 – KSQ Therapeutics emerged today with $76 million in…